Antimicrobial, antibiofilm and cytotoxic effects of a colloidal nanocarrier composed by chitosan-coated iron oxide nanoparticles loaded with chlorhexidine

Araujo, Heitor Ceolin; Silva, Ana Carolina Gomes da; Paião, Luana Isabel; Magario, Mychelle Keiko Watanabe; Frasnelli, Sabrina Cruz Tfaile; Oliveira, Sandra Helena Penha de; Pessan, Juliano Pelim; Monteiro, Douglas Roberto

doi:10.1016/j.jdent.2020.103453

Cited by 21 publications

(15 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall, the MTT assay revealed similar cytotoxicity rates for each antifungal and their respective nanocarriers, regardless of the exposure time ( Figure 3 ). Although a previous study found that IONPs and CS alone led to marked reductions in the viability of L929 cells for concentrations from 87.5 and 175 µg/mL, respectively [ 25 ], these compounds did not potentiate the cytotoxic effects of the IONPs-CS-FLZ and IONPs-CS-MCZ nanocarriers. In fact, the results of the present study indicate that the nanocarriers’ cytotoxicity is primarily dependent on the presence of the antifungals (FLZ and MCZ), corroborating a previous study in which the cytotoxicity of a cetylpyridinium chloride nanocarrier was also dependent on the presence of the drug, with no influence of the carrier compound (IONPs-CS) [ 26 ].…”

Section: Discussionmentioning

confidence: 85%

Nanocarriers of Miconazole or Fluconazole: Effects on Three-Species Candida Biofilms and Cytotoxic Effects In Vitro

Caldeirão

Araujo

Arias

et al. 2021

JoF

Self Cite

View full text Add to dashboard Cite

The contribution of different Candida species in oral fungal infections has stimulated the search for more effective therapies. This study assessed the antibiofilm effects of nanocarriers of miconazole (MCZ) or fluconazole (FLZ) on Candida biofilms, and their cytotoxic effects on murine fibroblasts. Three-species biofilms (Candida albicans/Candida glabrata/Candida tropicalis) were formed on 96-well plates, and they were treated with nanocarriers (iron oxide nanoparticles coated with chitosan—“IONPs-CS”) of MCZ or FLZ at 39/78/156 µg/mL; antifungals alone at 156 µg/mL and artificial saliva were tested as positive and negative controls, respectively. Biofilms were analyzed by colony forming units (CFU), biomass, metabolic activity, and structure/viability. The cytotoxicity (L929 cells) of all treatments was determined via 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT) reduction assay. Data were submitted to one- or two-way ANOVA, followed by Tukey’s or Fisher LSD’s tests (p < 0.05). IONPs-CS-MCZ at 78 µg/mL promoted similar antibiofilm and cytotoxic effects compared with MCZ at 156 µg/mL. In turn, IONPs-CS-FLZ at 156 µg/mL was overall the most effective FLZ antibiofilm treatment, surpassing the effects of FLZ alone; this nanocarrier was also less cytotoxic compared with FLZ alone. It can be concluded that both nanocarriers are more effective alternatives to fight Candida biofilms compared with their respective positive controls in vitro, being a promising alternative for the treatment of oral fungal infections.

show abstract

Section: Discussionmentioning

confidence: 85%

Nanocarriers of Miconazole or Fluconazole: Effects on Three-Species Candida Biofilms and Cytotoxic Effects In Vitro

Caldeirão

Araujo

Arias

et al. 2021

JoF

Self Cite

View full text Add to dashboard Cite

show abstract

“…After, chlorhexidine (CHX; 500 µg) was solubilized in CS-coated IONPs, and the suspension was stirred for 1 h to allow the nanocarrier formation. The amino group of CS interacts with both oxygen from IONPs and imine nitrogen group from CHX [126]. Reproduced with permission from Elsevier (Copyright©2020).…”

Section: Magnetic Nanoparticles (Mag Nps)mentioning

confidence: 99%

“…Another approach is to use metallic NPs possessing antimicrobial effectiveness in conjugation with polymeric NPs leading to periodontal diseases treatment of low toxi-city. Araujo et al [126] evaluated the antimicrobial and antibiofilm effects of colloidal nanocarrier iron oxide nanoparticles (IO NPs) coated with chitosan for chlorhexidine (CHX) on Candida glabrata and Enterococcus faecalis. They also tested the cytotoxic effect of this formulation on murine fibroblasts.…”

Section: Periodontal Drug Deliverymentioning

confidence: 99%

Advances in Chitosan-Based Nanoparticles for Drug Delivery

Mikušová

Mikuš

2021

IJMS

299

120

View full text Add to dashboard Cite

Nanoparticles (NPs) have an outstanding position in pharmaceutical, biological, and medical disciplines. Polymeric NPs based on chitosan (CS) can act as excellent drug carriers because of some intrinsic beneficial properties including biocompatibility, biodegradability, non-toxicity, bioactivity, easy preparation, and targeting specificity. Drug transport and release from CS-based particulate systems depend on the extent of cross-linking, morphology, size, and density of the particulate system, as well as physicochemical properties of the drug. All these aspects have to be considered when developing new CS-based NPs as potential drug delivery systems. This comprehensive review is summarizing and discussing recent advances in CS-based NPs being developed and examined for drug delivery. From this point of view, an enhancement of CS properties by its modification is presented. An enhancement in drug delivery by CS NPs is discussed in detail focusing on (i) a brief summarization of basic characteristics of CS NPs, (ii) a categorization of preparation procedures used for CS NPs involving also recent improvements in production schemes of conventional as well as novel CS NPs, (iii) a categorization and evaluation of CS-based-nanocomposites involving their production schemes with organic polymers and inorganic material, and (iv) very recent implementations of CS NPs and nanocomposites in drug delivery.

show abstract

“…The antimicrobial and antibiofilm effects of a colloidal nanocarrier for chlorhexidine (CHX) on yeast and bacteria such as Candida glabrata and Enterococcus faecalis were evaluated. The CHX nanocarrier has an excellent ability for the management of oral diseases linked to C. glabrata and E. faecalis [ 104 ].…”

Section: Applications Of Nanoantifungals In Veterinary Medicinementioning

confidence: 99%

Antifungal Nano-Therapy in Veterinary Medicine: Current Status and Future Prospects

Alghuthaymi

Hassan

Kalia

et al. 2021

JoF

View full text Add to dashboard Cite

The global recognition for the potential of nanoproducts and processes in human biomedicine has given impetus for the development of novel strategies for rapid, reliable, and proficient diagnosis, prevention, and control of animal diseases. Nanomaterials exhibit significant antifungal and antimycotoxin activities against mycosis and mycotoxicosis disorders in animals, as evidenced through reports published over the recent decade and more. These nanoantifungals can be potentially utilized for the development of a variety of products of pharmaceutical and biomedical significance including the nano-scale vaccines, adjuvants, anticancer and gene therapy systems, farm disinfectants, animal husbandry, and nutritional products. This review will provide details on the therapeutic and preventative aspects of nanoantifungals against diverse fungal and mycotoxin-related diseases in animals. The predominant mechanisms of action of these nanoantifungals and their potential as antifungal and cytotoxicity-causing agents will also be illustrated. Also, the other theragnostic applications of nanoantifungals in veterinary medicine will be identified.

show abstract

Antimicrobial, antibiofilm and cytotoxic effects of a colloidal nanocarrier composed by chitosan-coated iron oxide nanoparticles loaded with chlorhexidine

Cited by 21 publications

References 48 publications

Nanocarriers of Miconazole or Fluconazole: Effects on Three-Species Candida Biofilms and Cytotoxic Effects In Vitro

Nanocarriers of Miconazole or Fluconazole: Effects on Three-Species Candida Biofilms and Cytotoxic Effects In Vitro

Advances in Chitosan-Based Nanoparticles for Drug Delivery

Antifungal Nano-Therapy in Veterinary Medicine: Current Status and Future Prospects

Contact Info

Product

Resources

About